Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon

Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon

Abstract Background/purpose Lack of robust, feasible, and quantitative outcomes impedes Raynaud phenomenon (RP) clinical trials in systemic sclerosis (SSc) patients. Hyperspectral imaging (HSI) non-invasively measures oxygenated and deoxygenated hemoglobin (oxyHb and deoxyHb) concentrations and oxyg...

Full description

Bibliographic Details
Main Authors: Shannon Teaw, Akash Gupta, Alyssa Williams, F. Perry Wilson, Brandon J. Sumpio, Bauer E. Sumpio, Monique Hinchcliff
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Arthritis Research & Therapy
Subjects:
Systemic sclerosis
Scleroderma
Hyperspectral imaging
Raynaud phenomenon
Patient-reported outcome instruments
Imaging
Online Access:https://doi.org/10.1186/s13075-023-02990-3

Internet

https://doi.org/10.1186/s13075-023-02990-3

Similar Items